KJX839

Phase 3Small molecule

Novartis

KJX839 is one of 4 small molecule programs targeting Hypercholesterolaemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypercholesterolaemiaRecruiting

HypercholesterolaemiaPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Hypercholesterolaemia

#DrugCompanyPhaseTrials

Leqvio

Novartis

Phase 2

1 2

AZD0780

AstraZeneca

Phase 3

1 3

QCZ484

Novartis

Phase 2

1 4

KJX839

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Study completion

NCT06501443

Clinical

Trials by Indication[1]

Unspecified1 trial

LATAM LOWERS LDL-C

Recruiting· Novartis logo

Novartis·Phase 4·NCT06501443·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KJX839. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KJX839 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KJX839. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

KJX839

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News